Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| ALNYLAM PHARMACEUTICALS, INC.ALNY · Entity 3132 | Director | May 20, 2026 | May 22, 2026 |
| Elevance Health, Inc.ELV · Entity 2934 | Director | May 13, 2026 | May 15, 2026 |
| FRACTYL HEALTH, INC.GUTS · Entity 6700 | Director | June 11, 2025 | June 13, 2025 |
| Hudson Executive Investment Corp. IIHCII · Entity 130674 | Director | April 13, 2021 | April 14, 2021 |
| Korsana Biosciences, Inc.CYCN · Entity 7698 | Director | June 16, 2020 | June 18, 2020 |
| SQZ Biotechnologies CoSQZ · Entity 112267 | Director · 10% owner | June 14, 2023 | June 15, 2023 |
| Talkspace, Inc.HEC · Entity 22747 | Director | June 08, 2020 | June 08, 2020 |
| X4 Pharmaceuticals, IncASNS · Entity 5638 | Director | June 05, 2018 | June 07, 2018 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
ALNYLAM PHARMACEUTICALS, INC.
Report date May 20, 2026 · Filed May 22, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 24,049 |
Reported balance
After 2026-05-20 transaction · row 1
1 source rowRow 1 · 2026-05-20 · Grant · Acquired 838 · Balance 24,049 F1: These shares are represented by restricted stock units (RSUs) granted under the Second Amended and Restated 2018 Stock Incentive Plan. Each RSU represents a contingent right to receive one share of common stock. The RSUs will vest in full upon the earlier of the first anniversary of the grant date and the date of any earlier retirement or resignation of the Reporting Person, provided such date of retirement or resignation occurs no more than 90 days prior to the first anniversary of the grant date. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $298.48 · Expires 2036-05-20 | Direct | 1,802 |
Reported balance
After 2026-05-20 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-05-20 · Grant · Acquired 1,802 · Balance 1,802 F2: The stock option will vest in full upon the earlier of the first anniversary of the grant date and the date of any earlier retirement or resignation of the Reporting Person, provided such date of retirement or resignation occurs no more than 90 days prior to the first anniversary of the grant date. |
Filing footnotes · ownership attribution and instrument terms
F1: These shares are represented by restricted stock units (RSUs) granted under the Second Amended and Restated 2018 Stock Incentive Plan. Each RSU represents a contingent right to receive one share of common stock. The RSUs will vest in full upon the earlier of the first anniversary of the grant date and the date of any earlier retirement or resignation of the Reporting Person, provided such date of retirement or resignation occurs no more than 90 days prior to the first anniversary of the grant date.
F2: The stock option will vest in full upon the earlier of the first anniversary of the grant date and the date of any earlier retirement or resignation of the Reporting Person, provided such date of retirement or resignation occurs no more than 90 days prior to the first anniversary of the grant date.
Elevance Health, Inc.
Report date May 13, 2026 · Filed May 15, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 781 |
Reported balance
After 2026-05-13 transaction · row 1
1 source rowRow 1 · 2026-05-13 · Grant · Acquired 563 · Balance 781 F1: Deferred stock units accrued under the Elevance Health, Inc. ("Company") Board of Directors Compensation Program. F2: The deferred stock units shall be payable in Company common stock upon the first to occur of (a) five years from the date of grant or (b) the date the Reporting Person ceases to be a member of the Company's board of directors, unless a later date is designated in the Reporting Person's election made under the Company's Board of Directors Deferred Compensation Plan. |
Filing footnotes · ownership attribution and instrument terms
F1: Deferred stock units accrued under the Elevance Health, Inc. ("Company") Board of Directors Compensation Program.
F2: The deferred stock units shall be payable in Company common stock upon the first to occur of (a) five years from the date of grant or (b) the date the Reporting Person ceases to be a member of the Company's board of directors, unless a later date is designated in the Reporting Person's election made under the Company's Board of Directors Deferred Compensation Plan.
FRACTYL HEALTH, INC.
Report date June 11, 2025 · Filed June 13, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $2.27 · Expires 2035-06-10 | Direct | 22,500 |
Reported balance
After 2025-06-11 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2025-06-11 · Grant · Acquired 22,500 · Balance 22,500 F1: The stock option was awarded as compensation for the Reporting Person's service on the Issuer's board of directors pursuant to the Issuer's non-employee director compensation policy. The stock option will vest and become exercisable in a single installment on the earlier of (i) the date of the next annual meeting of stockholders or (ii) the first anniversary of the grant in each case subject to continued service on the Issuer's board of directors as a non-employee director through the vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The stock option was awarded as compensation for the Reporting Person's service on the Issuer's board of directors pursuant to the Issuer's non-employee director compensation policy. The stock option will vest and become exercisable in a single installment on the earlier of (i) the date of the next annual meeting of stockholders or (ii) the first anniversary of the grant in each case subject to continued service on the Issuer's board of directors as a non-employee director through the vesting date.
Hudson Executive Investment Corp. II
Report date April 13, 2021 · Filed April 14, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Class B Common StockSEC Table II · derivative / convertible security | Direct | 20,000 |
Reported balance
After 2021-04-13 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2021-04-13 · Purchase · Acquired 20,000 · Balance 20,000 F1: The shares of Class B common stock are convertible for shares of the Issuer's Class A common stock as described under the heading "Description of Securities" in the Issuer's Registration Statement on Form S-1 (File No. 333-251848) (the "Registration Statement") and have no expiration date |
Filing footnotes · ownership attribution and instrument terms
F1: The shares of Class B common stock are convertible for shares of the Issuer's Class A common stock as described under the heading "Description of Securities" in the Issuer's Registration Statement on Form S-1 (File No. 333-251848) (the "Registration Statement") and have no expiration date
Korsana Biosciences, Inc.
Report date June 16, 2020 · Filed June 18, 2020
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.46 · Expires 2030-06-16 | Direct | 10,000 |
Reported balance
After 2020-06-16 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2020-06-16 · Grant · Acquired 10,000 · Balance 10,000 F1: The options, granted pursuant to the director compensation plan, will vest in full on the first anniversary of the grant date. |
Filing footnotes · ownership attribution and instrument terms
F1: The options, granted pursuant to the director compensation plan, will vest in full on the first anniversary of the grant date.
SQZ Biotechnologies Co
Report date June 14, 2023 · Filed June 15, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $0.54 · Expires 2033-06-13 | Direct | 39,875 |
Reported balance
After 2023-06-14 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2023-06-14 · Grant · Acquired 39,875 · Balance 39,875 F1: The option vests and become exercisable on the earlier of (i) June 14, 2024 or (ii) the day immediately prior to the date of the next annual meeting of stockholders following the date of grant, in each case subject to the recipient's continued service on the Board at such time. |
Filing footnotes · ownership attribution and instrument terms
F1: The option vests and become exercisable on the earlier of (i) June 14, 2024 or (ii) the day immediately prior to the date of the next annual meeting of stockholders following the date of grant, in each case subject to the recipient's continued service on the Board at such time.
Talkspace, Inc.
Report date June 08, 2020 · Filed June 08, 2020
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Class B Common StockSEC Table II · derivative / convertible security | Direct | Not disclosed |
Reported balance
Holding disclosure · report date 2020-06-08 · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · Balance Not disclosed F1: The shares of Class B common stock are convertible for shares of the Issuer's Class A common stock as described under the heading "Description of Securities" in the Issuer's Registration Statement on Form S-1 (File No. 333-238583) (the "Registration Statement") and have no expiration date. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares of Class B common stock are convertible for shares of the Issuer's Class A common stock as described under the heading "Description of Securities" in the Issuer's Registration Statement on Form S-1 (File No. 333-238583) (the "Registration Statement") and have no expiration date.
X4 Pharmaceuticals, Inc
Report date June 05, 2018 · Filed June 07, 2018
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $16.99 · Expires 2028-06-04 | Direct | 10,000 |
Reported balance
After 2018-06-05 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2018-06-05 · Grant · Acquired 10,000 · Balance 10,000 F1: The option becomes exercisable as to 1/12th of the shares underlying the award on the one-month anniversary of the date of grant, with the remainder vesting in equal monthly installments until the first anniversary of the date of grant, subject to the Reporting Person's continued service as a director through each applicable vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The option becomes exercisable as to 1/12th of the shares underlying the award on the one-month anniversary of the date of grant, with the remainder vesting in equal monthly installments until the first anniversary of the date of grant, subject to the Reporting Person's continued service as a director through each applicable vesting date.
Past disclosures · reporting ended (4)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Blue Buffalo Pet Products, Inc.
Report date April 24, 2018 · Filed April 24, 2018
Section 16 reporting ended · disclosed 2018-04-24. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2018-04-24 transaction · row 1
1 source rowRow 1 · 2018-04-24 · Disposition to issuer · Disposed 14,819 · Balance 0 F1: On April 24, 2018, General Mills, Inc., a Delaware corporation ("Buyer"), acquired the Issuer pursuant to that certain Agreement and Plan of Merger entered into by and among the Issuer, Buyer and Bravo Merger Corp., a Delaware corporation and wholly-owned subsidiary of Buyer ("Merger Sub"), dated as of February 22, 2018 (the "Merger Agreement"). In accordance with the Merger Agreement, Merger Sub merged with and into the Issuer, with the Issuer surviving such merger as a wholly-owned subsidiary of Buyer (the "Merger"). F2: At the effective time of the Merger, each outstanding share of the Issuer's common stock (other than certain excluded shares) automatically converted into the right to receive $40.00 in cash, without interest and after giving effect to any required withholding taxes. |
Filing footnotes · ownership attribution and instrument terms
F1: On April 24, 2018, General Mills, Inc., a Delaware corporation ("Buyer"), acquired the Issuer pursuant to that certain Agreement and Plan of Merger entered into by and among the Issuer, Buyer and Bravo Merger Corp., a Delaware corporation and wholly-owned subsidiary of Buyer ("Merger Sub"), dated as of February 22, 2018 (the "Merger Agreement"). In accordance with the Merger Agreement, Merger Sub merged with and into the Issuer, with the Issuer surviving such merger as a wholly-owned subsidiary of Buyer (the "Merger").
F2: At the effective time of the Merger, each outstanding share of the Issuer's common stock (other than certain excluded shares) automatically converted into the right to receive $40.00 in cash, without interest and after giving effect to any required withholding taxes.
Camp4 Therapeutics Corp
Report date September 11, 2025 · Filed September 11, 2025
Jointly reported with Polaris Management Co. VII, L.L.C., Polaris Partners VII, L.P., Polaris Entrepreneurs' Fund VII, L.P., Polaris Partners X, L.P., Polaris Partners GP X, L.L.C., Chee Brian
Section 16 reporting ended · disclosed 2025-09-11. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectSee footnote | 2,825,500 |
Reported balance
After 2025-09-11 transaction · row 1
Holding and transaction disclosures are not merged.
1 source rowRow 1 · 2025-09-11 · Purchase · Acquired 1,221,721 · Balance 2,825,500 F1: On September 11, 2025, each of Polaris Partners VII, L.P. ("PP VII") and Polaris Entrepreneurs' Fund VII, L.P. ("PEF VII") acquired shares in a private placement by the Issuer pursuant to the terms of a Securities Purchase Agreement, dated as of September 9, 2025, by and among the Issuer and the investors party thereto at a purchase price of $1.53 per share. F2: The reported securities are owned directly by PP VII. Polaris Management Co. VII, L.L.C. ("PMC VII") is the general partner of PP VII. Each of David Barrett, Brian Chee, Amir Nashat, a member of the Issuer's board of directors, and Bryce Youngren (collectively, the "PMC VII Managing Members") are the managing members of PMC VII. Each of PMC VII and the PMC VII Managing Members in their respective capacities with respect to PMC VII, may be deemed to have shared voting, investment and dispositive power with respect to the securities held by PP VII. Each of PMC VII and the PMC VII Managing Members disclaims beneficial ownership of these securities and this report shall not be deemed an admission that any one of the PMC VII Managing Members or PMC VII is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein. |
| Common StockSEC Table I · non-derivative | IndirectSee footnote | 197,661 |
Reported balance
After 2025-09-11 transaction · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · 2025-09-11 · Purchase · Acquired 85,468 · Balance 197,661 F1: On September 11, 2025, each of Polaris Partners VII, L.P. ("PP VII") and Polaris Entrepreneurs' Fund VII, L.P. ("PEF VII") acquired shares in a private placement by the Issuer pursuant to the terms of a Securities Purchase Agreement, dated as of September 9, 2025, by and among the Issuer and the investors party thereto at a purchase price of $1.53 per share. F3: The reported securities are owned directly by PEF VII. PMC VII is the general partner of PEF VII. Each of PMC VII and the PMC VII Managing Members in their respective capacities with respect to PMC VII, may be deemed to have shared voting, investment and dispositive power with respect to the securities held by PEF VII. Each of PMC VII and the PMC VII Managing Members disclaims beneficial ownership of these securities and this report shall not be deemed an admission that any one of the PMC VII Managing Members or PMC VII is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein. |
| Common StockSEC Table I · non-derivative | IndirectSee footnote | 909,090 |
Reported balance
Holding disclosure · report date 2025-09-11 · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · Balance 909,090 F4: The reported securities are owned directly by Polaris Partners X, L.P. ("PP X"). Polaris Partners GP X, L.L.C. ("PPGP X") is the general partner of PP X. Each of Amy Schulman and Brian Chee are the managing members of PPGP X (the "PPGP X Managing Members"). Amir Nashat ("Mr. Nashat"), a member of the Issuer's board of directors, is an interest holder of PPGP X. Each of PPGP X, the PPGP X Managing Members and Mr. Nashat, in their respective capacities with respect to PPGP X, may be deemed to have shared voting, investment and dispositive power with respect to the securities held by PP X. Each of PPGP X, the PPGP X Managing Members and Mr. Nashat disclaims beneficial ownership of these securities and this report shall not be deemed an admission that any one of the PPGP X Managing Members, Mr. Nashat or PPGP X is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein. |
Filing footnotes · ownership attribution and instrument terms
F1: On September 11, 2025, each of Polaris Partners VII, L.P. ("PP VII") and Polaris Entrepreneurs' Fund VII, L.P. ("PEF VII") acquired shares in a private placement by the Issuer pursuant to the terms of a Securities Purchase Agreement, dated as of September 9, 2025, by and among the Issuer and the investors party thereto at a purchase price of $1.53 per share.
F2: The reported securities are owned directly by PP VII. Polaris Management Co. VII, L.L.C. ("PMC VII") is the general partner of PP VII. Each of David Barrett, Brian Chee, Amir Nashat, a member of the Issuer's board of directors, and Bryce Youngren (collectively, the "PMC VII Managing Members") are the managing members of PMC VII. Each of PMC VII and the PMC VII Managing Members in their respective capacities with respect to PMC VII, may be deemed to have shared voting, investment and dispositive power with respect to the securities held by PP VII. Each of PMC VII and the PMC VII Managing Members disclaims beneficial ownership of these securities and this report shall not be deemed an admission that any one of the PMC VII Managing Members or PMC VII is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein.
F3: The reported securities are owned directly by PEF VII. PMC VII is the general partner of PEF VII. Each of PMC VII and the PMC VII Managing Members in their respective capacities with respect to PMC VII, may be deemed to have shared voting, investment and dispositive power with respect to the securities held by PEF VII. Each of PMC VII and the PMC VII Managing Members disclaims beneficial ownership of these securities and this report shall not be deemed an admission that any one of the PMC VII Managing Members or PMC VII is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein.
F4: The reported securities are owned directly by Polaris Partners X, L.P. ("PP X"). Polaris Partners GP X, L.L.C. ("PPGP X") is the general partner of PP X. Each of Amy Schulman and Brian Chee are the managing members of PPGP X (the "PPGP X Managing Members"). Amir Nashat ("Mr. Nashat"), a member of the Issuer's board of directors, is an interest holder of PPGP X. Each of PPGP X, the PPGP X Managing Members and Mr. Nashat, in their respective capacities with respect to PPGP X, may be deemed to have shared voting, investment and dispositive power with respect to the securities held by PP X. Each of PPGP X, the PPGP X Managing Members and Mr. Nashat disclaims beneficial ownership of these securities and this report shall not be deemed an admission that any one of the PPGP X Managing Members, Mr. Nashat or PPGP X is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein.
IRONWOOD PHARMACEUTICALS INC
Report date April 01, 2019 · Filed April 03, 2019
Section 16 reporting ended · disclosed 2019-04-03. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Class A Common StockSEC Table I · non-derivative | Direct | 38,242 |
Reported balance
After 2019-04-01 transaction · row 1
1 source rowRow 1 · 2019-04-01 · Disposition to issuer · Disposed 4,056 · Balance 38,242 F1: Represents the disposition of 4,056 shares of restricted stock in connection with the separation of Cyclerion Therapeutics, Inc. ("Cyclerion") from Ironwood Pharmaceuticals, Inc. in exchange for restricted shares of Cyclerion Common Stock. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents the disposition of 4,056 shares of restricted stock in connection with the separation of Cyclerion Therapeutics, Inc. ("Cyclerion") from Ironwood Pharmaceuticals, Inc. in exchange for restricted shares of Cyclerion Common Stock.
PFIZER INC
Report date December 31, 2013 · Filed January 03, 2014
Section 16 reporting ended · disclosed 2014-01-03. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Phantom Stock Units SSPSEC Table II · derivative / convertible security | Direct | 5,075 |
Reported balance
After 2013-12-31 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2013-12-31 · Grant · Acquired 59 · Balance 5,075 F1: Each unit represents one phantom share of common stock. F2: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. |
Filing footnotes · ownership attribution and instrument terms
F1: Each unit represents one phantom share of common stock.
F2: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 20, 2026 Filed May 22, 2026 20:18 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | GrantStock Option (Right to Buy) · Derivative | 1,802 | $0.00 Strike: $298.48 | $0.00 |
DisclosureSEC source: 0001178670-26-000041 · form4.xml · derivative · entry 2 SCHULMAN AMY W · CIK 0001438226 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,802 Underlying: Common Stock · 1,802 shares Expires 2036-05-20 F2 · derivative.exercise_date: The stock option will vest in full upon the earlier of the first anniversary of the grant date and the date of any earlier retirement or resignation of the Reporting Person, provided such date of retirement or resignation occurs no more than 90 days prior to the first anniversary of the grant date. Read SEC document |
| May 20, 2026 Filed May 22, 2026 20:18 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | GrantCommon Stock | 838 | $0.00 | $0.00 |
DisclosureSEC source: 0001178670-26-000041 · form4.xml · nonDerivative · entry 1 SCHULMAN AMY W · CIK 0001438226 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 24,049 F1 · shares: These shares are represented by restricted stock units (RSUs) granted under the Second Amended and Restated 2018 Stock Incentive Plan. Each RSU represents a contingent right to receive one share of common stock. The RSUs will vest in full upon the earlier of the first anniversary of the grant date and the date of any earlier retirement or resignation of the Reporting Person, provided such date of retirement or resignation occurs no more than 90 days prior to the first anniversary of the grant date. Read SEC document |
| May 13, 2026 Filed May 14, 2026 20:17 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | Exercise / conversionStock Option (Right to Buy) · Derivative | 11,250 | $0.00 Strike: $70.20 | $0.00 |
DisclosureSEC source: 0001178670-26-000017 · form4.xml · derivative · entry 2 SCHULMAN AMY W · CIK 0001438226 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 11,250 shares Expires 2026-06-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The options exercised and held by the reporting person were due to expire on June 3, 2026. Read SEC document |
| May 13, 2026 Filed May 14, 2026 20:17 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | Exercise / conversionCommon Stock | 11,250 | $70.20 | $789,750.00 |
DisclosureSEC source: 0001178670-26-000017 · form4.xml · nonDerivative · entry 1 SCHULMAN AMY W · CIK 0001438226 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 23,211 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The options exercised and held by the reporting person were due to expire on June 3, 2026. Read SEC document |
| May 13, 2026 Filed May 15, 2026 20:16 UTC | Elevance Health, Inc. ELV · Entity 2934 | GrantCommon Stock | 563 | $0.00 | $0.00 |
DisclosureSEC source: 0001438226-26-000009 · wk-form4_1778876180.xml · nonDerivative · entry 1 SCHULMAN AMY W · CIK 0001438226 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 781 F1 · shares: Deferred stock units accrued under the Elevance Health, Inc. ("Company") Board of Directors Compensation Program. F2 · shares: The deferred stock units shall be payable in Company common stock upon the first to occur of (a) five years from the date of grant or (b) the date the Reporting Person ceases to be a member of the Company's board of directors, unless a later date is designated in the Reporting Person's election made under the Company's Board of Directors Deferred Compensation Plan. Read SEC document |
| March 12, 2026 Filed Mar 23, 2026 20:10 UTC | Elevance Health, Inc. ELV · Entity 2934 | SaleCommon Stock | 26 | $287.50 | $7,475.00 |
DisclosureSEC source: 0001438226-26-000007 · wk-form4_1774296634.xml · nonDerivative · entry 1 SCHULMAN AMY W · CIK 0001438226 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 218 Read SEC document |
| February 02, 2026 Filed Feb 3, 2026 21:42 UTC | Elevance Health, Inc. ELV · Entity 2934 | GrantCommon Stock | 218 | $0.00 | $0.00 |
DisclosureSEC source: 0001438226-26-000005 · wk-form4_1770154954.xml · nonDerivative · entry 1 SCHULMAN AMY W · CIK 0001438226 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 218 F1 · shares: Phantom Stock units accrued under the Elevance Health, Inc. ("Company") Board of Directors Compensation Program. F2 · shares: The phantom stock units shall be payable in Company common stock upon the first to occur of (a) five years from the date of the annual meeting of shareholders that immediately precedes the Director's election date or (b) the date the Reporting Person ceases to be a member of the Company's board of directors, unless a later date is designated in the Reporting Person's election made under the Company's Board of Directors Deferred Compensation Plan. Read SEC document |
| September 11, 2025 Filed Sep 11, 2025 20:59 UTC | Camp4 Therapeutics Corp CAMP · Entity 1161 | PurchaseCommon Stock | 85,468 | $1.53 | $130,766.04 |
DisclosureSEC source: 0001193125-25-201392 · ownership.xml · nonDerivative · entry 2 Polaris Management Co. VII, L.L.C. · CIK 0001678203 · 10% owner Polaris Partners VII, L.P. · CIK 0001611189 · 10% owner Polaris Entrepreneurs' Fund VII, L.P. · CIK 0001615991 · 10% owner Polaris Partners X, L.P. · CIK 0001910577 · 10% owner Polaris Partners GP X, L.L.C. · CIK 0001910575 · 10% owner SCHULMAN AMY W · CIK 0001438226 · 10% owner Chee Brian · CIK 0001295675 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 197,661 F1 · kind: On September 11, 2025, each of Polaris Partners VII, L.P. ("PP VII") and Polaris Entrepreneurs' Fund VII, L.P. ("PEF VII") acquired shares in a private placement by the Issuer pursuant to the terms of a Securities Purchase Agreement, dated as of September 9, 2025, by and among the Issuer and the investors party thereto at a purchase price of $1.53 per share. F3 · ownership.nature: The reported securities are owned directly by PEF VII. PMC VII is the general partner of PEF VII. Each of PMC VII and the PMC VII Managing Members in their respective capacities with respect to PMC VII, may be deemed to have shared voting, investment and dispositive power with respect to the securities held by PEF VII. Each of PMC VII and the PMC VII Managing Members disclaims beneficial ownership of these securities and this report shall not be deemed an admission that any one of the PMC VII Managing Members or PMC VII is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein. Read SEC document |
| September 11, 2025 Filed Sep 11, 2025 20:59 UTC | Camp4 Therapeutics Corp CAMP · Entity 1161 | PurchaseCommon Stock | 1,221,721 | $1.53 | $1,869,233.13 |
DisclosureSEC source: 0001193125-25-201392 · ownership.xml · nonDerivative · entry 1 Polaris Management Co. VII, L.L.C. · CIK 0001678203 · 10% owner Polaris Partners VII, L.P. · CIK 0001611189 · 10% owner Polaris Entrepreneurs' Fund VII, L.P. · CIK 0001615991 · 10% owner Polaris Partners X, L.P. · CIK 0001910577 · 10% owner Polaris Partners GP X, L.L.C. · CIK 0001910575 · 10% owner SCHULMAN AMY W · CIK 0001438226 · 10% owner Chee Brian · CIK 0001295675 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 2,825,500 F1 · kind: On September 11, 2025, each of Polaris Partners VII, L.P. ("PP VII") and Polaris Entrepreneurs' Fund VII, L.P. ("PEF VII") acquired shares in a private placement by the Issuer pursuant to the terms of a Securities Purchase Agreement, dated as of September 9, 2025, by and among the Issuer and the investors party thereto at a purchase price of $1.53 per share. F2 · ownership.nature: The reported securities are owned directly by PP VII. Polaris Management Co. VII, L.L.C. ("PMC VII") is the general partner of PP VII. Each of David Barrett, Brian Chee, Amir Nashat, a member of the Issuer's board of directors, and Bryce Youngren (collectively, the "PMC VII Managing Members") are the managing members of PMC VII. Each of PMC VII and the PMC VII Managing Members in their respective capacities with respect to PMC VII, may be deemed to have shared voting, investment and dispositive power with respect to the securities held by PP VII. Each of PMC VII and the PMC VII Managing Members disclaims beneficial ownership of these securities and this report shall not be deemed an admission that any one of the PMC VII Managing Members or PMC VII is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein. Read SEC document |
| June 11, 2025 Filed Jun 13, 2025 20:05 UTC | FRACTYL HEALTH, INC. GUTS · Entity 6700 | GrantStock Option · Derivative | 22,500 | $0.00 Strike: $2.27 | $0.00 |
DisclosureSEC source: 0000950170-25-086148 · ownership.xml · derivative · entry 1 SCHULMAN AMY W · CIK 0001438226 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 22,500 Underlying: Common Stock · 22,500 shares Expires 2035-06-10 F1 · derivative.exercise_date: The stock option was awarded as compensation for the Reporting Person's service on the Issuer's board of directors pursuant to the Issuer's non-employee director compensation policy. The stock option will vest and become exercisable in a single installment on the earlier of (i) the date of the next annual meeting of stockholders or (ii) the first anniversary of the grant in each case subject to continued service on the Issuer's board of directors as a non-employee director through the vesting date. Read SEC document |
| May 08, 2025 Filed May 12, 2025 20:04 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | GrantStock Option (right to buy) · Derivative | 1,558 | $0.00 Strike: $258.35 | $0.00 |
DisclosureSEC source: 0001735276-25-000061 · edgardoc.xml · derivative · entry 2 SCHULMAN AMY W · CIK 0001438226 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,558 Underlying: Common Stock · 1,558 shares Expires 2035-05-08 F2 · derivative.exercise_date: The stock option vests in full upon the earlier of the first anniversary of the grant date and the date of any earlier retirement or resignation of the Reporting Person, provided such date of retirement or resignation occurs no more than 90 days prior to the first anniversary of the grant date. Read SEC document |
| May 08, 2025 Filed May 12, 2025 20:04 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | GrantCommon Stock | 775 | $0.00 | $0.00 |
DisclosureSEC source: 0001735276-25-000061 · edgardoc.xml · nonDerivative · entry 1 SCHULMAN AMY W · CIK 0001438226 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,961 F1 · shares: These shares are represented by restricted stock units (RSUs) granted under the Amended and Restated 2018 Stock Incentive Plan. Each RSU represents a contingent right to receive one share of common stock. The RSUs will vest in full upon the earlier of the first anniversary of the grant date and the date of any earlier retirement or resignation of the Reporting Person, provided such date of retirement or resignation occurs no more than 90 days prior to the first anniversary of the grant date. Read SEC document |
| March 13, 2025 Filed Mar 14, 2025 20:16 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | Exercise / conversionStock Option (right to buy) · Derivative | 2,750 | $0.00 Strike: $131.21 | $0.00 |
DisclosureSEC source: 0001735276-25-000037 · edgardoc.xml · derivative · entry 2 SCHULMAN AMY W · CIK 0001438226 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,750 shares Expires 2025-06-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The options exercised and held by the reporting person were due to expire on June 1, 2025. F2 · derivative.exercise_date: The stock option was fully vested as of June 1, 2016. Read SEC document |
| March 13, 2025 Filed Mar 14, 2025 20:16 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | Exercise / conversionCommon Stock | 2,750 | $131.21 | $360,827.50 |
DisclosureSEC source: 0001735276-25-000037 · edgardoc.xml · nonDerivative · entry 1 SCHULMAN AMY W · CIK 0001438226 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,186 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The options exercised and held by the reporting person were due to expire on June 1, 2025. Read SEC document |
| March 13, 2025 Filed Mar 17, 2025 21:09 UTC | FRACTYL HEALTH, INC. GUTS · Entity 6700 | PurchaseCommon Stock | 8,550 | $1.17 | $9,964.17 |
DisclosureSEC source: 0000950170-25-040466 · ownership.xml · nonDerivative · entry 1 SCHULMAN AMY W · CIK 0001438226 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,550 F1 · kind: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from 1.165 to 1.17, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. Read SEC document |
| October 15, 2024 Filed Oct 15, 2024 22:00 UTC | Camp4 Therapeutics Corp CAMP · Entity 1161 | ConversionSeries B Preferred Stock · Derivative | 277,536 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950170-24-114788 · ownership.xml · derivative · entry 9 Polaris Management Co. VII, L.L.C. · CIK 0001678203 · 10% owner Polaris Partners VII, L.P. · CIK 0001611189 · 10% owner Polaris Entrepreneurs' Fund VII, L.P. · CIK 0001615991 · 10% owner Polaris Partners X, L.P. · CIK 0001910577 · 10% owner Polaris Partners GP X, L.L.C. · CIK 0001910575 · 10% owner SCHULMAN AMY W · CIK 0001438226 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnote Disclosed balance after: 0 Underlying: Common Stock · 24,745 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_price: On October 15, 2024, the shares of Series B Preferred Stock automatically converted into shares of Common Stock on a 11.2158-for-one basis without payment of further consideration upon the closing of the Issuer's initial public offering. The shares have no expiration date. F4 · price: On October 15, 2024, the shares of Series B Preferred Stock automatically converted into shares of Common Stock on a 11.2158-for-one basis without payment of further consideration upon the closing of the Issuer's initial public offering. The shares have no expiration date. F4 · derivative.exercise_date: On October 15, 2024, the shares of Series B Preferred Stock automatically converted into shares of Common Stock on a 11.2158-for-one basis without payment of further consideration upon the closing of the Issuer's initial public offering. The shares have no expiration date. F4 · derivative.expiration_date: On October 15, 2024, the shares of Series B Preferred Stock automatically converted into shares of Common Stock on a 11.2158-for-one basis without payment of further consideration upon the closing of the Issuer's initial public offering. The shares have no expiration date. F3 · ownership.nature: The reported securities are owned directly by Polaris Entrepreneurs' Fund VII, L.P. ("PEF VII"). PMC VII is the general partner of PEF VII. Each of PMC VII and the PMC VII Managing Members in their respective capacities with respect to PMC VII, may be deemed to have shared voting, investment and dispositive power with respect to the securities held by PEF VII. Each of PMC VII and the PMC VII Managing Members disclaims beneficial ownership of these securities and this report shall not be deemed an admission that any one of the PMC VII Managing Members or PMC VII is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein. Read SEC document |
| October 15, 2024 Filed Oct 15, 2024 22:00 UTC | Camp4 Therapeutics Corp CAMP · Entity 1161 | ConversionSeries B Preferred Stock · Derivative | 3,967,234 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950170-24-114788 · ownership.xml · derivative · entry 8 Polaris Management Co. VII, L.L.C. · CIK 0001678203 · 10% owner Polaris Partners VII, L.P. · CIK 0001611189 · 10% owner Polaris Entrepreneurs' Fund VII, L.P. · CIK 0001615991 · 10% owner Polaris Partners X, L.P. · CIK 0001910577 · 10% owner Polaris Partners GP X, L.L.C. · CIK 0001910575 · 10% owner SCHULMAN AMY W · CIK 0001438226 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnote Disclosed balance after: 0 Underlying: Common Stock · 353,718 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_price: On October 15, 2024, the shares of Series B Preferred Stock automatically converted into shares of Common Stock on a 11.2158-for-one basis without payment of further consideration upon the closing of the Issuer's initial public offering. The shares have no expiration date. F4 · price: On October 15, 2024, the shares of Series B Preferred Stock automatically converted into shares of Common Stock on a 11.2158-for-one basis without payment of further consideration upon the closing of the Issuer's initial public offering. The shares have no expiration date. F4 · derivative.exercise_date: On October 15, 2024, the shares of Series B Preferred Stock automatically converted into shares of Common Stock on a 11.2158-for-one basis without payment of further consideration upon the closing of the Issuer's initial public offering. The shares have no expiration date. F4 · derivative.expiration_date: On October 15, 2024, the shares of Series B Preferred Stock automatically converted into shares of Common Stock on a 11.2158-for-one basis without payment of further consideration upon the closing of the Issuer's initial public offering. The shares have no expiration date. F2 · ownership.nature: The reported securities are owned directly by Polaris Partners VII, L.P. ("PP VII"). Polaris Management Co. VII, L.L.C. ("PMC VII") is the general partner of PP VII. Each of David Barrett, Brian Chee, Amir Nashat, a member of the Issuer's board of directors, and Bryce Youngren (collectively, the "PMC VII Managing Members") are the managing members of PMC VII. Each of PMC VII and the PMC VII Managing Members in their respective capacities with respect to PMC VII, may be deemed to have shared voting, investment and dispositive power with respect to the securities held by PP VII. Each of PMC VII and the PMC VII Managing Members disclaims beneficial ownership of these securities and this report shall not be deemed an admission that any one of the PMC VII Managing Members or PMC VII is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein. Read SEC document |
| October 15, 2024 Filed Oct 15, 2024 22:00 UTC | Camp4 Therapeutics Corp CAMP · Entity 1161 | ConversionSeries A Prime Preferred Stock · Derivative | 980,829 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950170-24-114788 · ownership.xml · derivative · entry 7 Polaris Management Co. VII, L.L.C. · CIK 0001678203 · 10% owner Polaris Partners VII, L.P. · CIK 0001611189 · 10% owner Polaris Entrepreneurs' Fund VII, L.P. · CIK 0001615991 · 10% owner Polaris Partners X, L.P. · CIK 0001910577 · 10% owner Polaris Partners GP X, L.L.C. · CIK 0001910575 · 10% owner SCHULMAN AMY W · CIK 0001438226 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnote Disclosed balance after: 0 Underlying: Common Stock · 87,448 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: On October 15, 2024, the shares of Series A Prime Convertible Preferred Stock automatically converted into shares of Common Stock on a 11.2158-for-one basis without payment of further consideration upon the closing of the Issuer's initial public offering. The shares have no expiration date. F1 · price: On October 15, 2024, the shares of Series A Prime Convertible Preferred Stock automatically converted into shares of Common Stock on a 11.2158-for-one basis without payment of further consideration upon the closing of the Issuer's initial public offering. The shares have no expiration date. F1 · derivative.exercise_date: On October 15, 2024, the shares of Series A Prime Convertible Preferred Stock automatically converted into shares of Common Stock on a 11.2158-for-one basis without payment of further consideration upon the closing of the Issuer's initial public offering. The shares have no expiration date. F1 · derivative.expiration_date: On October 15, 2024, the shares of Series A Prime Convertible Preferred Stock automatically converted into shares of Common Stock on a 11.2158-for-one basis without payment of further consideration upon the closing of the Issuer's initial public offering. The shares have no expiration date. F3 · ownership.nature: The reported securities are owned directly by Polaris Entrepreneurs' Fund VII, L.P. ("PEF VII"). PMC VII is the general partner of PEF VII. Each of PMC VII and the PMC VII Managing Members in their respective capacities with respect to PMC VII, may be deemed to have shared voting, investment and dispositive power with respect to the securities held by PEF VII. Each of PMC VII and the PMC VII Managing Members disclaims beneficial ownership of these securities and this report shall not be deemed an admission that any one of the PMC VII Managing Members or PMC VII is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein. Read SEC document |
| October 15, 2024 Filed Oct 15, 2024 22:00 UTC | Camp4 Therapeutics Corp CAMP · Entity 1161 | ConversionSeries A Prime Preferred Stock · Derivative | 14,020,475 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950170-24-114788 · ownership.xml · derivative · entry 6 Polaris Management Co. VII, L.L.C. · CIK 0001678203 · 10% owner Polaris Partners VII, L.P. · CIK 0001611189 · 10% owner Polaris Entrepreneurs' Fund VII, L.P. · CIK 0001615991 · 10% owner Polaris Partners X, L.P. · CIK 0001910577 · 10% owner Polaris Partners GP X, L.L.C. · CIK 0001910575 · 10% owner SCHULMAN AMY W · CIK 0001438226 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnote Disclosed balance after: 0 Underlying: Common Stock · 1,250,061 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: On October 15, 2024, the shares of Series A Prime Convertible Preferred Stock automatically converted into shares of Common Stock on a 11.2158-for-one basis without payment of further consideration upon the closing of the Issuer's initial public offering. The shares have no expiration date. F1 · price: On October 15, 2024, the shares of Series A Prime Convertible Preferred Stock automatically converted into shares of Common Stock on a 11.2158-for-one basis without payment of further consideration upon the closing of the Issuer's initial public offering. The shares have no expiration date. F1 · derivative.exercise_date: On October 15, 2024, the shares of Series A Prime Convertible Preferred Stock automatically converted into shares of Common Stock on a 11.2158-for-one basis without payment of further consideration upon the closing of the Issuer's initial public offering. The shares have no expiration date. F1 · derivative.expiration_date: On October 15, 2024, the shares of Series A Prime Convertible Preferred Stock automatically converted into shares of Common Stock on a 11.2158-for-one basis without payment of further consideration upon the closing of the Issuer's initial public offering. The shares have no expiration date. F2 · ownership.nature: The reported securities are owned directly by Polaris Partners VII, L.P. ("PP VII"). Polaris Management Co. VII, L.L.C. ("PMC VII") is the general partner of PP VII. Each of David Barrett, Brian Chee, Amir Nashat, a member of the Issuer's board of directors, and Bryce Youngren (collectively, the "PMC VII Managing Members") are the managing members of PMC VII. Each of PMC VII and the PMC VII Managing Members in their respective capacities with respect to PMC VII, may be deemed to have shared voting, investment and dispositive power with respect to the securities held by PP VII. Each of PMC VII and the PMC VII Managing Members disclaims beneficial ownership of these securities and this report shall not be deemed an admission that any one of the PMC VII Managing Members or PMC VII is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein. Read SEC document |
| October 15, 2024 Filed Oct 15, 2024 22:00 UTC | Camp4 Therapeutics Corp CAMP · Entity 1161 | PurchaseCommon Stock | 909,090 | $11.00 | $9,999,990.00 |
DisclosureSEC source: 0000950170-24-114788 · ownership.xml · nonDerivative · entry 5 Polaris Management Co. VII, L.L.C. · CIK 0001678203 · 10% owner Polaris Partners VII, L.P. · CIK 0001611189 · 10% owner Polaris Entrepreneurs' Fund VII, L.P. · CIK 0001615991 · 10% owner Polaris Partners X, L.P. · CIK 0001910577 · 10% owner Polaris Partners GP X, L.L.C. · CIK 0001910575 · 10% owner SCHULMAN AMY W · CIK 0001438226 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 909,090 F5 · ownership.nature: The reported securities are owned directly by Polaris Partners X, L.P. ("PP X"). Polaris Partners GP X, L.L.C. ("PPGP X") is the general partner of PP X. Each of Amy Schulman and Brian Chee are the managing members of PPGP X (the "PPGP X Managing Members"). Amir Nashat ("Mr. Nashat"), a member of the Issuer's board of directors, is an interest holder of PPGP X. Each of PPGP X, the PPGP X Managing Members and Mr. Nashat, in their respective capacities with respect to PPGP X, may be deemed to have shared voting, investment and dispositive power with respect to the securities held by PP X. Each of PPGP X, the PPGP X Managing Members and Mr. Nashat disclaims beneficial ownership of these securities and this report shall not be deemed an admission that any one of the PPGP X Managing Members, Mr. Nashat or PPGP X is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein. Read SEC document |
| October 15, 2024 Filed Oct 15, 2024 22:00 UTC | Camp4 Therapeutics Corp CAMP · Entity 1161 | ConversionCommon Stock | 24,745 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950170-24-114788 · ownership.xml · nonDerivative · entry 4 Polaris Management Co. VII, L.L.C. · CIK 0001678203 · 10% owner Polaris Partners VII, L.P. · CIK 0001611189 · 10% owner Polaris Entrepreneurs' Fund VII, L.P. · CIK 0001615991 · 10% owner Polaris Partners X, L.P. · CIK 0001910577 · 10% owner Polaris Partners GP X, L.L.C. · CIK 0001910575 · 10% owner SCHULMAN AMY W · CIK 0001438226 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 112,193 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · kind: On October 15, 2024, the shares of Series B Preferred Stock automatically converted into shares of Common Stock on a 11.2158-for-one basis without payment of further consideration upon the closing of the Issuer's initial public offering. The shares have no expiration date. F4 · price: On October 15, 2024, the shares of Series B Preferred Stock automatically converted into shares of Common Stock on a 11.2158-for-one basis without payment of further consideration upon the closing of the Issuer's initial public offering. The shares have no expiration date. F3 · ownership.nature: The reported securities are owned directly by Polaris Entrepreneurs' Fund VII, L.P. ("PEF VII"). PMC VII is the general partner of PEF VII. Each of PMC VII and the PMC VII Managing Members in their respective capacities with respect to PMC VII, may be deemed to have shared voting, investment and dispositive power with respect to the securities held by PEF VII. Each of PMC VII and the PMC VII Managing Members disclaims beneficial ownership of these securities and this report shall not be deemed an admission that any one of the PMC VII Managing Members or PMC VII is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein. Read SEC document |
| October 15, 2024 Filed Oct 15, 2024 22:00 UTC | Camp4 Therapeutics Corp CAMP · Entity 1161 | ConversionCommon Stock | 353,718 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950170-24-114788 · ownership.xml · nonDerivative · entry 3 Polaris Management Co. VII, L.L.C. · CIK 0001678203 · 10% owner Polaris Partners VII, L.P. · CIK 0001611189 · 10% owner Polaris Entrepreneurs' Fund VII, L.P. · CIK 0001615991 · 10% owner Polaris Partners X, L.P. · CIK 0001910577 · 10% owner Polaris Partners GP X, L.L.C. · CIK 0001910575 · 10% owner SCHULMAN AMY W · CIK 0001438226 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 1,603,779 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · kind: On October 15, 2024, the shares of Series B Preferred Stock automatically converted into shares of Common Stock on a 11.2158-for-one basis without payment of further consideration upon the closing of the Issuer's initial public offering. The shares have no expiration date. F4 · price: On October 15, 2024, the shares of Series B Preferred Stock automatically converted into shares of Common Stock on a 11.2158-for-one basis without payment of further consideration upon the closing of the Issuer's initial public offering. The shares have no expiration date. F2 · ownership.nature: The reported securities are owned directly by Polaris Partners VII, L.P. ("PP VII"). Polaris Management Co. VII, L.L.C. ("PMC VII") is the general partner of PP VII. Each of David Barrett, Brian Chee, Amir Nashat, a member of the Issuer's board of directors, and Bryce Youngren (collectively, the "PMC VII Managing Members") are the managing members of PMC VII. Each of PMC VII and the PMC VII Managing Members in their respective capacities with respect to PMC VII, may be deemed to have shared voting, investment and dispositive power with respect to the securities held by PP VII. Each of PMC VII and the PMC VII Managing Members disclaims beneficial ownership of these securities and this report shall not be deemed an admission that any one of the PMC VII Managing Members or PMC VII is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein. Read SEC document |
| October 15, 2024 Filed Oct 15, 2024 22:00 UTC | Camp4 Therapeutics Corp CAMP · Entity 1161 | ConversionCommon Stock | 87,448 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950170-24-114788 · ownership.xml · nonDerivative · entry 2 Polaris Management Co. VII, L.L.C. · CIK 0001678203 · 10% owner Polaris Partners VII, L.P. · CIK 0001611189 · 10% owner Polaris Entrepreneurs' Fund VII, L.P. · CIK 0001615991 · 10% owner Polaris Partners X, L.P. · CIK 0001910577 · 10% owner Polaris Partners GP X, L.L.C. · CIK 0001910575 · 10% owner SCHULMAN AMY W · CIK 0001438226 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 87,448 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: On October 15, 2024, the shares of Series A Prime Convertible Preferred Stock automatically converted into shares of Common Stock on a 11.2158-for-one basis without payment of further consideration upon the closing of the Issuer's initial public offering. The shares have no expiration date. F1 · price: On October 15, 2024, the shares of Series A Prime Convertible Preferred Stock automatically converted into shares of Common Stock on a 11.2158-for-one basis without payment of further consideration upon the closing of the Issuer's initial public offering. The shares have no expiration date. F3 · ownership.nature: The reported securities are owned directly by Polaris Entrepreneurs' Fund VII, L.P. ("PEF VII"). PMC VII is the general partner of PEF VII. Each of PMC VII and the PMC VII Managing Members in their respective capacities with respect to PMC VII, may be deemed to have shared voting, investment and dispositive power with respect to the securities held by PEF VII. Each of PMC VII and the PMC VII Managing Members disclaims beneficial ownership of these securities and this report shall not be deemed an admission that any one of the PMC VII Managing Members or PMC VII is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein. Read SEC document |
| October 15, 2024 Filed Oct 15, 2024 22:00 UTC | Camp4 Therapeutics Corp CAMP · Entity 1161 | ConversionCommon Stock | 1,250,061 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950170-24-114788 · ownership.xml · nonDerivative · entry 1 Polaris Management Co. VII, L.L.C. · CIK 0001678203 · 10% owner Polaris Partners VII, L.P. · CIK 0001611189 · 10% owner Polaris Entrepreneurs' Fund VII, L.P. · CIK 0001615991 · 10% owner Polaris Partners X, L.P. · CIK 0001910577 · 10% owner Polaris Partners GP X, L.L.C. · CIK 0001910575 · 10% owner SCHULMAN AMY W · CIK 0001438226 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 1,250,061 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: On October 15, 2024, the shares of Series A Prime Convertible Preferred Stock automatically converted into shares of Common Stock on a 11.2158-for-one basis without payment of further consideration upon the closing of the Issuer's initial public offering. The shares have no expiration date. F1 · price: On October 15, 2024, the shares of Series A Prime Convertible Preferred Stock automatically converted into shares of Common Stock on a 11.2158-for-one basis without payment of further consideration upon the closing of the Issuer's initial public offering. The shares have no expiration date. F2 · ownership.nature: The reported securities are owned directly by Polaris Partners VII, L.P. ("PP VII"). Polaris Management Co. VII, L.L.C. ("PMC VII") is the general partner of PP VII. Each of David Barrett, Brian Chee, Amir Nashat, a member of the Issuer's board of directors, and Bryce Youngren (collectively, the "PMC VII Managing Members") are the managing members of PMC VII. Each of PMC VII and the PMC VII Managing Members in their respective capacities with respect to PMC VII, may be deemed to have shared voting, investment and dispositive power with respect to the securities held by PP VII. Each of PMC VII and the PMC VII Managing Members disclaims beneficial ownership of these securities and this report shall not be deemed an admission that any one of the PMC VII Managing Members or PMC VII is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein. Read SEC document |
| October 15, 2024 Filed Oct 22, 2024 21:31 UTC Amendment | Camp4 Therapeutics Corp CAMP · Entity 1161 | ConversionSeries B Preferred Stock · Derivative | 277,536 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950170-24-116360 · ownership.xml · derivative · entry 9 Polaris Management Co. VII, L.L.C. · CIK 0001678203 · 10% owner Polaris Partners VII, L.P. · CIK 0001611189 · 10% owner Polaris Entrepreneurs' Fund VII, L.P. · CIK 0001615991 · 10% owner Polaris Partners X, L.P. · CIK 0001910577 · 10% owner Polaris Partners GP X, L.L.C. · CIK 0001910575 · 10% owner SCHULMAN AMY W · CIK 0001438226 · 10% owner Chee Brian · CIK 0001295675 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnote Disclosed balance after: 0 Underlying: Common Stock · 24,745 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_price: On October 15, 2024, the shares of Series B Preferred Stock automatically converted into shares of Common Stock on a 11.2158-for-one basis without payment of further consideration upon the closing of the Issuer's initial public offering. The shares have no expiration date. F4 · price: On October 15, 2024, the shares of Series B Preferred Stock automatically converted into shares of Common Stock on a 11.2158-for-one basis without payment of further consideration upon the closing of the Issuer's initial public offering. The shares have no expiration date. F4 · derivative.exercise_date: On October 15, 2024, the shares of Series B Preferred Stock automatically converted into shares of Common Stock on a 11.2158-for-one basis without payment of further consideration upon the closing of the Issuer's initial public offering. The shares have no expiration date. F4 · derivative.expiration_date: On October 15, 2024, the shares of Series B Preferred Stock automatically converted into shares of Common Stock on a 11.2158-for-one basis without payment of further consideration upon the closing of the Issuer's initial public offering. The shares have no expiration date. F3 · ownership.nature: The reported securities are owned directly by Polaris Entrepreneurs' Fund VII, L.P. ("PEF VII"). PMC VII is the general partner of PEF VII. Each of PMC VII and the PMC VII Managing Members in their respective capacities with respect to PMC VII, may be deemed to have shared voting, investment and dispositive power with respect to the securities held by PEF VII. Each of PMC VII and the PMC VII Managing Members disclaims beneficial ownership of these securities and this report shall not be deemed an admission that any one of the PMC VII Managing Members or PMC VII is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein. Read SEC document |
| October 15, 2024 Filed Oct 22, 2024 21:31 UTC Amendment | Camp4 Therapeutics Corp CAMP · Entity 1161 | ConversionSeries B Preferred Stock · Derivative | 3,967,234 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950170-24-116360 · ownership.xml · derivative · entry 8 Polaris Management Co. VII, L.L.C. · CIK 0001678203 · 10% owner Polaris Partners VII, L.P. · CIK 0001611189 · 10% owner Polaris Entrepreneurs' Fund VII, L.P. · CIK 0001615991 · 10% owner Polaris Partners X, L.P. · CIK 0001910577 · 10% owner Polaris Partners GP X, L.L.C. · CIK 0001910575 · 10% owner SCHULMAN AMY W · CIK 0001438226 · 10% owner Chee Brian · CIK 0001295675 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnote Disclosed balance after: 0 Underlying: Common Stock · 353,718 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_price: On October 15, 2024, the shares of Series B Preferred Stock automatically converted into shares of Common Stock on a 11.2158-for-one basis without payment of further consideration upon the closing of the Issuer's initial public offering. The shares have no expiration date. F4 · price: On October 15, 2024, the shares of Series B Preferred Stock automatically converted into shares of Common Stock on a 11.2158-for-one basis without payment of further consideration upon the closing of the Issuer's initial public offering. The shares have no expiration date. F4 · derivative.exercise_date: On October 15, 2024, the shares of Series B Preferred Stock automatically converted into shares of Common Stock on a 11.2158-for-one basis without payment of further consideration upon the closing of the Issuer's initial public offering. The shares have no expiration date. F4 · derivative.expiration_date: On October 15, 2024, the shares of Series B Preferred Stock automatically converted into shares of Common Stock on a 11.2158-for-one basis without payment of further consideration upon the closing of the Issuer's initial public offering. The shares have no expiration date. F2 · ownership.nature: The reported securities are owned directly by Polaris Partners VII, L.P. ("PP VII"). Polaris Management Co. VII, L.L.C. ("PMC VII") is the general partner of PP VII. Each of David Barrett, Brian Chee, Amir Nashat, a member of the Issuer's board of directors, and Bryce Youngren (collectively, the "PMC VII Managing Members") are the managing members of PMC VII. Each of PMC VII and the PMC VII Managing Members in their respective capacities with respect to PMC VII, may be deemed to have shared voting, investment and dispositive power with respect to the securities held by PP VII. Each of PMC VII and the PMC VII Managing Members disclaims beneficial ownership of these securities and this report shall not be deemed an admission that any one of the PMC VII Managing Members or PMC VII is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein. Read SEC document |
| October 15, 2024 Filed Oct 22, 2024 21:31 UTC Amendment | Camp4 Therapeutics Corp CAMP · Entity 1161 | ConversionSeries A Prime Preferred Stock · Derivative | 980,829 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950170-24-116360 · ownership.xml · derivative · entry 7 Polaris Management Co. VII, L.L.C. · CIK 0001678203 · 10% owner Polaris Partners VII, L.P. · CIK 0001611189 · 10% owner Polaris Entrepreneurs' Fund VII, L.P. · CIK 0001615991 · 10% owner Polaris Partners X, L.P. · CIK 0001910577 · 10% owner Polaris Partners GP X, L.L.C. · CIK 0001910575 · 10% owner SCHULMAN AMY W · CIK 0001438226 · 10% owner Chee Brian · CIK 0001295675 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnote Disclosed balance after: 0 Underlying: Common Stock · 87,448 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: On October 15, 2024, the shares of Series A Prime Convertible Preferred Stock automatically converted into shares of Common Stock on a 11.2158-for-one basis without payment of further consideration upon the closing of the Issuer's initial public offering. The shares have no expiration date. F1 · price: On October 15, 2024, the shares of Series A Prime Convertible Preferred Stock automatically converted into shares of Common Stock on a 11.2158-for-one basis without payment of further consideration upon the closing of the Issuer's initial public offering. The shares have no expiration date. F1 · derivative.exercise_date: On October 15, 2024, the shares of Series A Prime Convertible Preferred Stock automatically converted into shares of Common Stock on a 11.2158-for-one basis without payment of further consideration upon the closing of the Issuer's initial public offering. The shares have no expiration date. F1 · derivative.expiration_date: On October 15, 2024, the shares of Series A Prime Convertible Preferred Stock automatically converted into shares of Common Stock on a 11.2158-for-one basis without payment of further consideration upon the closing of the Issuer's initial public offering. The shares have no expiration date. F3 · ownership.nature: The reported securities are owned directly by Polaris Entrepreneurs' Fund VII, L.P. ("PEF VII"). PMC VII is the general partner of PEF VII. Each of PMC VII and the PMC VII Managing Members in their respective capacities with respect to PMC VII, may be deemed to have shared voting, investment and dispositive power with respect to the securities held by PEF VII. Each of PMC VII and the PMC VII Managing Members disclaims beneficial ownership of these securities and this report shall not be deemed an admission that any one of the PMC VII Managing Members or PMC VII is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein. Read SEC document |
| October 15, 2024 Filed Oct 22, 2024 21:31 UTC Amendment | Camp4 Therapeutics Corp CAMP · Entity 1161 | ConversionSeries A Prime Preferred Stock · Derivative | 14,020,475 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950170-24-116360 · ownership.xml · derivative · entry 6 Polaris Management Co. VII, L.L.C. · CIK 0001678203 · 10% owner Polaris Partners VII, L.P. · CIK 0001611189 · 10% owner Polaris Entrepreneurs' Fund VII, L.P. · CIK 0001615991 · 10% owner Polaris Partners X, L.P. · CIK 0001910577 · 10% owner Polaris Partners GP X, L.L.C. · CIK 0001910575 · 10% owner SCHULMAN AMY W · CIK 0001438226 · 10% owner Chee Brian · CIK 0001295675 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnote Disclosed balance after: 0 Underlying: Common Stock · 1,250,061 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: On October 15, 2024, the shares of Series A Prime Convertible Preferred Stock automatically converted into shares of Common Stock on a 11.2158-for-one basis without payment of further consideration upon the closing of the Issuer's initial public offering. The shares have no expiration date. F1 · price: On October 15, 2024, the shares of Series A Prime Convertible Preferred Stock automatically converted into shares of Common Stock on a 11.2158-for-one basis without payment of further consideration upon the closing of the Issuer's initial public offering. The shares have no expiration date. F1 · derivative.exercise_date: On October 15, 2024, the shares of Series A Prime Convertible Preferred Stock automatically converted into shares of Common Stock on a 11.2158-for-one basis without payment of further consideration upon the closing of the Issuer's initial public offering. The shares have no expiration date. F1 · derivative.expiration_date: On October 15, 2024, the shares of Series A Prime Convertible Preferred Stock automatically converted into shares of Common Stock on a 11.2158-for-one basis without payment of further consideration upon the closing of the Issuer's initial public offering. The shares have no expiration date. F2 · ownership.nature: The reported securities are owned directly by Polaris Partners VII, L.P. ("PP VII"). Polaris Management Co. VII, L.L.C. ("PMC VII") is the general partner of PP VII. Each of David Barrett, Brian Chee, Amir Nashat, a member of the Issuer's board of directors, and Bryce Youngren (collectively, the "PMC VII Managing Members") are the managing members of PMC VII. Each of PMC VII and the PMC VII Managing Members in their respective capacities with respect to PMC VII, may be deemed to have shared voting, investment and dispositive power with respect to the securities held by PP VII. Each of PMC VII and the PMC VII Managing Members disclaims beneficial ownership of these securities and this report shall not be deemed an admission that any one of the PMC VII Managing Members or PMC VII is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein. Read SEC document |
| October 15, 2024 Filed Oct 22, 2024 21:31 UTC Amendment | Camp4 Therapeutics Corp CAMP · Entity 1161 | PurchaseCommon Stock | 909,090 | $11.00 | $9,999,990.00 |
DisclosureSEC source: 0000950170-24-116360 · ownership.xml · nonDerivative · entry 5 Polaris Management Co. VII, L.L.C. · CIK 0001678203 · 10% owner Polaris Partners VII, L.P. · CIK 0001611189 · 10% owner Polaris Entrepreneurs' Fund VII, L.P. · CIK 0001615991 · 10% owner Polaris Partners X, L.P. · CIK 0001910577 · 10% owner Polaris Partners GP X, L.L.C. · CIK 0001910575 · 10% owner SCHULMAN AMY W · CIK 0001438226 · 10% owner Chee Brian · CIK 0001295675 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 909,090 F5 · ownership.nature: The reported securities are owned directly by Polaris Partners X, L.P. ("PP X"). Polaris Partners GP X, L.L.C. ("PPGP X") is the general partner of PP X. Each of Amy Schulman and Brian Chee are the managing members of PPGP X (the "PPGP X Managing Members"). Amir Nashat ("Mr. Nashat"), a member of the Issuer's board of directors, is an interest holder of PPGP X. Each of PPGP X, the PPGP X Managing Members and Mr. Nashat, in their respective capacities with respect to PPGP X, may be deemed to have shared voting, investment and dispositive power with respect to the securities held by PP X. Each of PPGP X, the PPGP X Managing Members and Mr. Nashat disclaims beneficial ownership of these securities and this report shall not be deemed an admission that any one of the PPGP X Managing Members, Mr. Nashat or PPGP X is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein. Read SEC document |
| October 15, 2024 Filed Oct 22, 2024 21:31 UTC Amendment | Camp4 Therapeutics Corp CAMP · Entity 1161 | ConversionCommon Stock | 24,745 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950170-24-116360 · ownership.xml · nonDerivative · entry 4 Polaris Management Co. VII, L.L.C. · CIK 0001678203 · 10% owner Polaris Partners VII, L.P. · CIK 0001611189 · 10% owner Polaris Entrepreneurs' Fund VII, L.P. · CIK 0001615991 · 10% owner Polaris Partners X, L.P. · CIK 0001910577 · 10% owner Polaris Partners GP X, L.L.C. · CIK 0001910575 · 10% owner SCHULMAN AMY W · CIK 0001438226 · 10% owner Chee Brian · CIK 0001295675 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 112,193 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · kind: On October 15, 2024, the shares of Series B Preferred Stock automatically converted into shares of Common Stock on a 11.2158-for-one basis without payment of further consideration upon the closing of the Issuer's initial public offering. The shares have no expiration date. F4 · price: On October 15, 2024, the shares of Series B Preferred Stock automatically converted into shares of Common Stock on a 11.2158-for-one basis without payment of further consideration upon the closing of the Issuer's initial public offering. The shares have no expiration date. F3 · ownership.nature: The reported securities are owned directly by Polaris Entrepreneurs' Fund VII, L.P. ("PEF VII"). PMC VII is the general partner of PEF VII. Each of PMC VII and the PMC VII Managing Members in their respective capacities with respect to PMC VII, may be deemed to have shared voting, investment and dispositive power with respect to the securities held by PEF VII. Each of PMC VII and the PMC VII Managing Members disclaims beneficial ownership of these securities and this report shall not be deemed an admission that any one of the PMC VII Managing Members or PMC VII is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein. Read SEC document |
| October 15, 2024 Filed Oct 22, 2024 21:31 UTC Amendment | Camp4 Therapeutics Corp CAMP · Entity 1161 | ConversionCommon Stock | 353,718 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950170-24-116360 · ownership.xml · nonDerivative · entry 3 Polaris Management Co. VII, L.L.C. · CIK 0001678203 · 10% owner Polaris Partners VII, L.P. · CIK 0001611189 · 10% owner Polaris Entrepreneurs' Fund VII, L.P. · CIK 0001615991 · 10% owner Polaris Partners X, L.P. · CIK 0001910577 · 10% owner Polaris Partners GP X, L.L.C. · CIK 0001910575 · 10% owner SCHULMAN AMY W · CIK 0001438226 · 10% owner Chee Brian · CIK 0001295675 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 1,603,779 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · kind: On October 15, 2024, the shares of Series B Preferred Stock automatically converted into shares of Common Stock on a 11.2158-for-one basis without payment of further consideration upon the closing of the Issuer's initial public offering. The shares have no expiration date. F4 · price: On October 15, 2024, the shares of Series B Preferred Stock automatically converted into shares of Common Stock on a 11.2158-for-one basis without payment of further consideration upon the closing of the Issuer's initial public offering. The shares have no expiration date. F2 · ownership.nature: The reported securities are owned directly by Polaris Partners VII, L.P. ("PP VII"). Polaris Management Co. VII, L.L.C. ("PMC VII") is the general partner of PP VII. Each of David Barrett, Brian Chee, Amir Nashat, a member of the Issuer's board of directors, and Bryce Youngren (collectively, the "PMC VII Managing Members") are the managing members of PMC VII. Each of PMC VII and the PMC VII Managing Members in their respective capacities with respect to PMC VII, may be deemed to have shared voting, investment and dispositive power with respect to the securities held by PP VII. Each of PMC VII and the PMC VII Managing Members disclaims beneficial ownership of these securities and this report shall not be deemed an admission that any one of the PMC VII Managing Members or PMC VII is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein. Read SEC document |
| October 15, 2024 Filed Oct 22, 2024 21:31 UTC Amendment | Camp4 Therapeutics Corp CAMP · Entity 1161 | ConversionCommon Stock | 87,448 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950170-24-116360 · ownership.xml · nonDerivative · entry 2 Polaris Management Co. VII, L.L.C. · CIK 0001678203 · 10% owner Polaris Partners VII, L.P. · CIK 0001611189 · 10% owner Polaris Entrepreneurs' Fund VII, L.P. · CIK 0001615991 · 10% owner Polaris Partners X, L.P. · CIK 0001910577 · 10% owner Polaris Partners GP X, L.L.C. · CIK 0001910575 · 10% owner SCHULMAN AMY W · CIK 0001438226 · 10% owner Chee Brian · CIK 0001295675 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 87,448 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: On October 15, 2024, the shares of Series A Prime Convertible Preferred Stock automatically converted into shares of Common Stock on a 11.2158-for-one basis without payment of further consideration upon the closing of the Issuer's initial public offering. The shares have no expiration date. F1 · price: On October 15, 2024, the shares of Series A Prime Convertible Preferred Stock automatically converted into shares of Common Stock on a 11.2158-for-one basis without payment of further consideration upon the closing of the Issuer's initial public offering. The shares have no expiration date. F3 · ownership.nature: The reported securities are owned directly by Polaris Entrepreneurs' Fund VII, L.P. ("PEF VII"). PMC VII is the general partner of PEF VII. Each of PMC VII and the PMC VII Managing Members in their respective capacities with respect to PMC VII, may be deemed to have shared voting, investment and dispositive power with respect to the securities held by PEF VII. Each of PMC VII and the PMC VII Managing Members disclaims beneficial ownership of these securities and this report shall not be deemed an admission that any one of the PMC VII Managing Members or PMC VII is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein. Read SEC document |
| October 15, 2024 Filed Oct 22, 2024 21:31 UTC Amendment | Camp4 Therapeutics Corp CAMP · Entity 1161 | ConversionCommon Stock | 1,250,061 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950170-24-116360 · ownership.xml · nonDerivative · entry 1 Polaris Management Co. VII, L.L.C. · CIK 0001678203 · 10% owner Polaris Partners VII, L.P. · CIK 0001611189 · 10% owner Polaris Entrepreneurs' Fund VII, L.P. · CIK 0001615991 · 10% owner Polaris Partners X, L.P. · CIK 0001910577 · 10% owner Polaris Partners GP X, L.L.C. · CIK 0001910575 · 10% owner SCHULMAN AMY W · CIK 0001438226 · 10% owner Chee Brian · CIK 0001295675 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 1,250,061 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: On October 15, 2024, the shares of Series A Prime Convertible Preferred Stock automatically converted into shares of Common Stock on a 11.2158-for-one basis without payment of further consideration upon the closing of the Issuer's initial public offering. The shares have no expiration date. F1 · price: On October 15, 2024, the shares of Series A Prime Convertible Preferred Stock automatically converted into shares of Common Stock on a 11.2158-for-one basis without payment of further consideration upon the closing of the Issuer's initial public offering. The shares have no expiration date. F2 · ownership.nature: The reported securities are owned directly by Polaris Partners VII, L.P. ("PP VII"). Polaris Management Co. VII, L.L.C. ("PMC VII") is the general partner of PP VII. Each of David Barrett, Brian Chee, Amir Nashat, a member of the Issuer's board of directors, and Bryce Youngren (collectively, the "PMC VII Managing Members") are the managing members of PMC VII. Each of PMC VII and the PMC VII Managing Members in their respective capacities with respect to PMC VII, may be deemed to have shared voting, investment and dispositive power with respect to the securities held by PP VII. Each of PMC VII and the PMC VII Managing Members disclaims beneficial ownership of these securities and this report shall not be deemed an admission that any one of the PMC VII Managing Members or PMC VII is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein. Read SEC document |
| June 25, 2024 Filed Jun 27, 2024 20:04 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | Exercise / conversionStock Option (right to buy) · Derivative | 8,500 | $0.00 Strike: $131.21 | $0.00 |
DisclosureSEC source: 0001735276-24-000072 · edgardoc.xml · derivative · entry 3 SCHULMAN AMY W · CIK 0001438226 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 2,750 Underlying: Common Stock · 8,500 shares Expires 2025-06-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: All transactions reported on this Form 4 were made pursuant to a Rule 10b5-1(c) trading plan adopted by the reporting person on February 28, 2024. F2 · derivative.exercise_date: This stock option was fully vested and exercisable as of June 1, 2016. Read SEC document |
| June 25, 2024 Filed Jun 27, 2024 20:04 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | SaleCommon Stock | 8,500 | $240.00 | $2,040,000.00 |
DisclosureSEC source: 0001735276-24-000072 · edgardoc.xml · nonDerivative · entry 2 SCHULMAN AMY W · CIK 0001438226 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 8,436 F1 · kind: All transactions reported on this Form 4 were made pursuant to a Rule 10b5-1(c) trading plan adopted by the reporting person on February 28, 2024. Read SEC document |
| June 25, 2024 Filed Jun 27, 2024 20:04 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | Exercise / conversionCommon Stock | 8,500 | $131.21 | $1,115,285.00 |
DisclosureSEC source: 0001735276-24-000072 · edgardoc.xml · nonDerivative · entry 1 SCHULMAN AMY W · CIK 0001438226 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 16,936 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: All transactions reported on this Form 4 were made pursuant to a Rule 10b5-1(c) trading plan adopted by the reporting person on February 28, 2024. Read SEC document |
| May 29, 2024 Filed May 31, 2024 23:00 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | Exercise / conversionStock Option (right to buy) · Derivative | 30,000 | $0.00 Strike: $66.83 | $0.00 |
DisclosureSEC source: 0001735276-24-000058 · edgardoc.xml · derivative · entry 5 SCHULMAN AMY W · CIK 0001438226 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 30,000 shares Expires 2024-07-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Reflects shares sold to cover option cost and tax obligations upon the option exercise pursuant to a Rule 10b5-1(c) trading plan adopted by the reporting person on February 28, 2024. The 30,000 options exercised by the reporting person were due to expire on July 1, 2024. F4 · derivative.exercise_date: This stock option was fully vested and exercisable as of July 1, 2017. Read SEC document |
| May 29, 2024 Filed May 31, 2024 23:00 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | SaleCommon Stock | 63 | $149.76 | $9,434.88 |
DisclosureSEC source: 0001735276-24-000058 · edgardoc.xml · nonDerivative · entry 4 SCHULMAN AMY W · CIK 0001438226 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 8,436 F1 · kind: Reflects shares sold to cover option cost and tax obligations upon the option exercise pursuant to a Rule 10b5-1(c) trading plan adopted by the reporting person on February 28, 2024. The 30,000 options exercised by the reporting person were due to expire on July 1, 2024. Read SEC document |
| May 29, 2024 Filed May 31, 2024 23:00 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | SaleCommon Stock | 11,516 | $148.93 | $1,715,077.88 |
DisclosureSEC source: 0001735276-24-000058 · edgardoc.xml · nonDerivative · entry 3 SCHULMAN AMY W · CIK 0001438226 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 8,499 F1 · kind: Reflects shares sold to cover option cost and tax obligations upon the option exercise pursuant to a Rule 10b5-1(c) trading plan adopted by the reporting person on February 28, 2024. The 30,000 options exercised by the reporting person were due to expire on July 1, 2024. F3 · price: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $148.63 to $149.52. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| May 29, 2024 Filed May 31, 2024 23:00 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | SaleCommon Stock | 10,121 | $148.21 | $1,500,033.41 |
DisclosureSEC source: 0001735276-24-000058 · edgardoc.xml · nonDerivative · entry 2 SCHULMAN AMY W · CIK 0001438226 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 20,015 F1 · kind: Reflects shares sold to cover option cost and tax obligations upon the option exercise pursuant to a Rule 10b5-1(c) trading plan adopted by the reporting person on February 28, 2024. The 30,000 options exercised by the reporting person were due to expire on July 1, 2024. F2 · price: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $147.62 to $148.60. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| May 29, 2024 Filed May 31, 2024 23:00 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | Exercise / conversionCommon Stock | 30,000 | $66.83 | $2,004,900.00 |
DisclosureSEC source: 0001735276-24-000058 · edgardoc.xml · nonDerivative · entry 1 SCHULMAN AMY W · CIK 0001438226 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 30,136 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Reflects shares sold to cover option cost and tax obligations upon the option exercise pursuant to a Rule 10b5-1(c) trading plan adopted by the reporting person on February 28, 2024. The 30,000 options exercised by the reporting person were due to expire on July 1, 2024. Read SEC document |
| May 16, 2024 Filed May 20, 2024 20:04 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | GrantStock Option (right to buy) · Derivative | 5,228 | $0.00 Strike: $151.22 | $0.00 |
DisclosureSEC source: 0001735276-24-000047 · edgardoc.xml · derivative · entry 1 SCHULMAN AMY W · CIK 0001438226 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,228 Underlying: Common Stock · 5,228 shares Expires 2034-05-16 F1 · derivative.exercise_date: This award vests in full upon the earlier of the first anniversary of the grant date and the date of any earlier retirement or resignation of the Reporting Person, provided such date of retirement or resignation occurs no more than 90 days prior to the first anniversary of the grant date. Read SEC document |
| February 01, 2024 Filed Feb 5, 2024 22:05 UTC | FRACTYL HEALTH, INC. GUTS · Entity 6700 | GrantStock Option · Derivative | 45,000 | $0.00 Strike: $15.00 | $0.00 |
DisclosureSEC source: 0000950170-24-011323 · ownership.xml · derivative · entry 1 SCHULMAN AMY W · CIK 0001438226 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 45,000 Underlying: Common Stock · 45,000 shares Expires 2034-01-31 F1 · derivative.exercise_date: The stock option vests in three annual installments beginning on February 1, 2025. Read SEC document |
| June 14, 2023 Filed Jun 15, 2023 20:46 UTC | SQZ Biotechnologies Co SQZ · Entity 112267 | GrantStock Option · Derivative | 39,875 | $0.00 Strike: $0.54 | $0.00 |
DisclosureSEC source: 0001209191-23-037386 · doc4.xml · derivative · entry 1 SCHULMAN AMY W · CIK 0001438226 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 39,875 Underlying: Common Stock · 39,875 shares Expires 2033-06-13 F1 · derivative.exercise_date: The option vests and become exercisable on the earlier of (i) June 14, 2024 or (ii) the day immediately prior to the date of the next annual meeting of stockholders following the date of grant, in each case subject to the recipient's continued service on the Board at such time. Read SEC document |
| May 18, 2023 Filed May 19, 2023 20:04 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | GrantStock Option (right to buy) · Derivative | 3,454 | $0.00 Strike: $189.87 | $0.00 |
DisclosureSEC source: 0001735276-23-000063 · edgardoc.xml · derivative · entry 1 SCHULMAN AMY W · CIK 0001438226 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,454 Underlying: Common Stock · 3,454 shares Expires 2033-05-18 F1 · derivative.exercise_date: This award vests in full upon the earlier of the first anniversary of the grant date and the date of any earlier retirement or resignation of the Reporting Person, provided such date of retirement or resignation occurs no more than 90 days prior to the first anniversary of the grant date. Read SEC document |
| February 23, 2023 Filed Feb 27, 2023 21:13 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | Exercise / conversionRestricted Stock Units · Derivative | 136 | $0.00 | $0.00 |
DisclosureSEC source: 0001735276-23-000019 · edgardoc.xml · derivative · entry 2 SCHULMAN AMY W · CIK 0001438226 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 136 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of ALNY common stock. F2 · derivative.exercise_date: This award vested on February 23, 2023, the first anniversary of the grant date. F2 · derivative.expiration_date: This award vested on February 23, 2023, the first anniversary of the grant date. Read SEC document |
| February 23, 2023 Filed Feb 27, 2023 21:13 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | Exercise / conversionCommon Stock | 136 | $0.00 | $0.00 |
DisclosureSEC source: 0001735276-23-000019 · edgardoc.xml · nonDerivative · entry 1 SCHULMAN AMY W · CIK 0001438226 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 136 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 15, 2022 Filed Jun 16, 2022 21:01 UTC | SQZ Biotechnologies Co SQZ · Entity 112267 | GrantStock Option · Derivative | 20,000 | $0.00 Strike: $3.23 | $0.00 |
DisclosureSEC source: 0001209191-22-037493 · doc4.xml · derivative · entry 1 SCHULMAN AMY W · CIK 0001438226 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2032-06-14 F1 · derivative.exercise_date: The option vests and become exercisable on the earlier of (i) June 15, 2023 or (ii) the day immediately prior to the date of the next annual meeting of stockholders following the date of grant, in each case subject to the recipient's continued service on the Board at such time. Read SEC document |
| May 18, 2022 Filed May 20, 2022 20:06 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | GrantStock Option (right to buy) · Derivative | 5,153 | $0.00 Strike: $128.31 | $0.00 |
DisclosureSEC source: 0001735276-22-000051 · edgardoc.xml · derivative · entry 1 SCHULMAN AMY W · CIK 0001438226 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,153 Underlying: Common Stock · 5,153 shares Expires 2032-05-17 F1 · derivative.exercise_date: This award vests in full upon the earlier of the first anniversary of the grant date and the date of any earlier retirement or resignation of the Reporting Person, provided such date of retirement or resignation occurs no more than 90 days prior to the first anniversary of the grant date. Read SEC document |
| February 23, 2022 Filed Feb 25, 2022 21:09 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | GrantRestricted Stock Units · Derivative | 136 | $0.00 | $0.00 |
DisclosureSEC source: 0001735276-22-000029 · edgardoc.xml · derivative · entry 1 SCHULMAN AMY W · CIK 0001438226 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 136 Underlying: Common Stock · 136 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of ALNY common stock. F2 · derivative.exercise_date: This award vests in full upon the earlier of the first anniversary of the grant date and the date of any earlier retirement or resignation of the Reporting Person, provided such date of retirement or resignation occurs no more than 90 days prior to the first anniversary of the grant date. F2 · derivative.expiration_date: This award vests in full upon the earlier of the first anniversary of the grant date and the date of any earlier retirement or resignation of the Reporting Person, provided such date of retirement or resignation occurs no more than 90 days prior to the first anniversary of the grant date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.